) --




) hit a new 52-week high Wednesday as it is currently trading at $94.80, above its previous 52-week high of $94.76 with 237,063 shares traded as of 11:16 a.m. ET. Average volume has been 516,700 shares over the past 30 days.

Shire has a market cap of $17.4 billion and is part of the

health care

sector and


industry. Shares are up 28.8% year to date as of the previous trading day's close.

Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in two segments, Specialty Pharmaceuticals and Human Genetic Therapies. The company has a P/E ratio of 29.3, above the average drugs industry P/E ratio of 27.5 and above the S&P 500 P/E ratio of 17.7.

  • Practice your SHPGY trading strategies and win cash in our stock game.

TheStreet Ratings rates Shire as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. You can view the full

Shire Ratings Report


See all

52-week high stocks

or get investment ideas from our

investment research center